CLS Special Populations in Lipid Management Flashcards
6 cards from real CLS practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 6 CLS Special Populations in Lipid Management flashcards as text
Which lipid-lowering medication is absolutely contraindicated in pregnancy due to teratogenicity?
Answer: Statins
Statins are absolutely contraindicated in pregnancy (Category X) because cholesterol is essential for fetal development and statins are teratogenic.
In patients with chronic kidney disease (CKD) stages 3–5 not on dialysis, which lipid-lowering therapy is recommended by KDIGO guidelines?
Answer: Statin or statin/ezetimibe combination
KDIGO guidelines recommend statin or statin/ezetimibe combination therapy for CKD stages 3–5 not on dialysis to reduce cardiovascular risk.
What is the recommended approach to lipid-lowering therapy in patients on hemodialysis, based on evidence from the 4D and AURORA trials?
Answer: Statins should not be initiated de novo in dialysis patients but may be continued if already prescribed
The 4D and AURORA trials showed no cardiovascular benefit from initiating statins in dialysis patients, so current guidelines recommend not starting them de novo in this population.
In patients with HIV on antiretroviral therapy, which statin is preferred due to minimal interaction with protease inhibitors?
Answer: Pravastatin or rosuvastatin
Pravastatin and rosuvastatin are preferred in HIV patients on protease inhibitors because they have minimal CYP3A4 metabolism, avoiding dangerous drug interactions.
Which physiologic change during pregnancy normally causes triglyceride levels to increase?
Answer: Increased estrogen stimulates hepatic VLDL production
Estrogen during pregnancy stimulates hepatic VLDL production, causing a physiologic rise in triglycerides that can unmask underlying hypertriglyceridemia disorders.
In elderly patients (>75 years) without established cardiovascular disease, the decision to initiate statin therapy should prioritize which consideration?
Answer: Shared decision-making weighing benefit, polypharmacy, functional status, and life expectancy
In elderly patients for primary prevention, guidelines emphasize individualized shared decision-making given limited trial data, polypharmacy concerns, and varying life expectancy.
How this page was made: written with AI tools. Exam facts are checked against the official sources listed below. Not reviewed by a subject-matter expert. Editorial policy
Sources & references
Exam facts on this page (fees, format, dates, passing scores) are checked against these official sources; the date is our last check. Editorial policy
- lipidboard.org — Renewal, score validity, test delivery, exam format, time limit, fees, registration deadline, test dates · verified Oct 2026